|
J Biol Chem, Vol. 275, Issue 17, 12963-12969, April 28, 2000
Structural Determinants for Post-transcriptional
Stabilization of Lactate Dehydrogenase A mRNA by the Protein
Kinase C Signal Pathway*
Sabine
Short,
Di
Tian,
Marc L.
Short, and
Richard A.
Jungmann
From the Department of Cellular and Molecular Biology and Cancer
Center, Northwestern University Medical School,
Chicago, Illinois 60611-3008
 |
ABSTRACT |
Activation of protein kinase C (PKC) and protein
kinase A (PKA) in rat C6 glioma cells increases the half-life of
short-lived lactate dehydrogenase (LDH)-A mRNA about 5- and 8-fold,
respectively. PKA and PKC act synergistically and prolong LDH-A
mRNA half-life more than 21-fold. Similar effects were observed
after transfection and transcription of a globin/lactate dehydrogenase
minigene consisting of a -globin expression vector in which the
3'-untranslated region (UTR) of -globin had been replaced with the
LDH-A 3'-UTR. Synergism was only obtained by transcription of minigenes
containing the entire 3'-UTR and did not occur when truncated 3'-UTR
fragments were analyzed. Additional mutational analyses showed that a
20-nucleotide region, named PKC-stabilizing region (PCSR), is
responsible for mediating the stabilizing effect of PKC. Previous
studies (Tian, D., Huang, D., Short, S., Short, M. L., and
Jungmann, R. A. (1998) J. Biol. Chem. 273, 24861-24866) have demonstrated the existence of a cAMP-stabilizing
region in LDH-A 3'-UTR. Sequence analysis of PCSR identified a
13-nucleotide AU-rich region that is common to both cAMP-stabilizing
region and PCSR. These studies identify a specific PKC-responsive
stabilizing element and indicate that interaction of PKA and PKC
results in a potentiating effect on LDH-A mRNA stabilization.
 |
INTRODUCTION |
During recent years we have established evidence for a bimodal
mechanism of LDH-A1
regulation involving transcriptional as well as post-transcriptional modulation of LDH-A expression (1-6). Both mechanisms are regulated by
a number of agonists of intracellular signaling pathways. For instance,
agonists of PKA and PKC can modify the metabolic functions of cells by
inducing an altered program of LDH-A mRNA regulation. These
mechanisms allow the cell to respond rapidly to changes in the
physiologic environment of the cell and to cover a potential energy
deficit through conversion of pyruvate to lactate. Clues to mechanisms
underlying this dual mode of control were provided by the
identification of cis-acting promoter elements instrumental in PKA- and PKC-mediated transcriptional regulation (2, 6). However,
less information is available about the mechanism of protein
kinase-mediated LDH-A mRNA stability regulation resulting in higher
levels of intracellular LDH-A mRNA (3).
Attention has recently focused on the modulation of mRNA stability
in response to a variety of physiological signals. For instance, it is
known that activators of PKA and PKC are important effectors of
mRNA stability regulation in a number of gene systems (1, 3, 5,
7-14). Our own studies identified a synergistic interaction between
PKA and PKC in regulating the stability of LDH-A mRNA (3). Whereas
the molecular basis for the synergistic effect remains unknown, we have
recently identified a cAMP-stabilizing region (CSR) within the
3'-UTR of LDH-A mRNA (5) that in combination with specific
CSR-binding proteins (4) is required to achieve LDH-A mRNA
stabilization in response to PKA activation. The binding activity of
the proteins to the CSR and the effect on LDH-A mRNA stabilization
are regulated through a phosphorylation/dephosphorylation mechanism by
PKA and as yet unknown protein phosphatases. Thus, it is now clear that
the CSR, in concert with CSR-binding proteins, is absolutely required
to achieve increased LDH-A mRNA stability in response to PKA
activation. However, the molecular mechanism of mRNA stabilization
by PKC is unknown.
The present paper describes the identification of a
cis-regulatory element within the 3'-UTR of LDH-A mRNA
that is required for PKC-mediated mRNA stability regulation. The
identification was accomplished using a strategy previously developed
for the identification of the cAMP-stabilizing region (5). Using
deletion, mutation, and replacement analysis, we constructed chimeric
-globin/ldh 3'-UTR minigenes that were stably transfected
and expressed in rat C6 glioma cells. Applying ribonuclease protection
assays, we studied the effects of PKC activation on the rate of decay of chimeric -globin/ldh 3'-UTR mRNAs. Using this
methodology, we demonstrated the presence of an uridine-rich region
within the LDH-A 3'-UTR, named PKC-stabilizing region (PCSR), capable of stabilizing LDH-A mRNA in response PKC activation. It is of particular interest that the sequences of CSR and PCSR overlap and
possess a common 13-nucleotide region.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Nucleic acid-modifying enzymes, acrylamide, and
nucleoside triphosphates were from Roche Molecular Biochemicals.
Radioisotopes were purchased from NEN Life Science Products. Other
reagents were of molecular biology grade and purchased from Sigma. Cell culture products were purchased from Life Technologies, Inc.
Synthetic Oligonucleotides--
Synthesis and processing of
synthetic DNA oligonucleotides and their ligation into respective
plasmid vectors were performed as described before (5).
Cell Culture--
Rat C6 glioma cells (American Type Culture
Collection CCL 107) were maintained as monolayers in Ham's F-10
nutrient medium supplemented with 10% dialyzed fetal calf serum, 50 units/ml of penicillin, and 50 mg of streptomycin as described by us
(5).
Plasmids--
The LDH-A 3'-UTR was derived from plasmid pLDH-2
(kindly provided by Dr. Richard Breathnach) containing a full-length
rat fibroblast LDH-A cDNA insert. The mRNA consists of a
103-nucleotide 5'-untranslated region and a 510-nucleotide
3'-untranslated region (corresponding to nucleotides 1103-1610) (50).
The 3'-UTR contains the classic polyadenylation signal AAUAAA 18 nucleotides before the poly(A) sequence. A
HinfI/BamHI fragment containing the entire LDH-A
3'-UTR (with 28-base pair 5' coding sequence and 100-base pair pLDH-2
vector sequence) was inserted into pGEM3Zf( ) at the BamHI
site resulting in plasmid pLDH-5. To eliminate the 28-base pair
ldh-a coding and 100-base pair pLDH-2 vector sequences
contained in pLDH-5, the complete 510-base pair 3'-UTR of LDH-A with 5' BamHI and 3' HindIII sites was amplified by
polymerase chain reaction. The fragment was cloned into the
BamHI-HindIII sites of pBluescript II KS+
(Stratagene) resulting in pLDH-6 from which the various 3'-UTR
fragments were prepared.
Construction of Wild-type and Mutant Globin/ldh
cDNAs--
The rabbit -globin expression vector pRc/FBB (see
Fig. 1) was constructed as described previously (5) by Dr. D. Chagnovich (Northwestern University) in two steps from plasmids pRc/CMS
(Invitrogen) and pBBB (kindly provided by Dr. M. E. Greenberg)
(15). Plasmid pRc/FBB encodes a transcription unit consisting of
-globin coding region flanked by the -globin 5'- and
3'-untranslated regions fused to the c-fos promoter.
To construct the chimeric globin/ldh expression vectors,
various LDH-A 3'-UTR fragments were inserted into the BglII
site or, alternatively, they replaced the BglII/Hind III fragment
( -globin 3'-UTR) of pRc/FBB. The fragments were constructed as
follows. To construct the pRc/FBB expression vector containing the
full-length LDH-A 3'-UTR, the 510-base pair 3'-UTR was polymerase chain
reaction-amplified from pLDH-6 using 5'- and 3'-oligonucleotide primers
with BglII and HindIII restriction sites,
respectively. The polymerase chain reaction product as well as pRc/FBB
were digested with BglII and HindIII and ligated
to generate expression vector pRc/FBB/LDH. In this vector, the
-globin 3'-UTR had been deleted from pRc/FBB and replaced with the
LDH-A 3'-UTR. Truncated 3'-UTR fragments were similarly generated using
the appropriate oligonucleotide primers. Fragments for insertion into
the BglII site of pRc/FBB were blunt-end ligated, and
fragments replacing the globin 3'-UTR contained BglII and
HindIII ends.
LDH-A 3'-UTR sequences with base deletions were generated by splicing
upstream and downstream polymerase chain reaction fragments that lacked
the appropriate base sequence as indicated in Fig. 3. The sequence and
correct orientation of all inserts were confirmed by restriction and
DNA sequence analyses. Sequencing was carried out in both directions by
the dideoxynucleotide chain terminator method with specific synthetic
oligonucleotides as primers.
Stable Transfection with Expression Vectors and Selection of
G418-resistant Clones--
These experimental methods were described
in detail in a previous publication (5).
Cell Stimulation--
All experiments were carried out at about
90% confluence. Serum was withdrawn 24-28 h prior to addition of
fetal bovine serum (final concentration, 15%) together with various
agents at concentrations indicated in the text. One hour after the
addition (taken as 0 h time point), RNA was isolated at subsequent
time points up to 12 h and analyzed.
RNA Preparation and mRNA Half-life Measurements--
These
methods were previously described in detail (5). Messenger RNA decay
was assessed by ribonuclease protection assay. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as internal control, because GAPDH mRNA was stable under the conditions of the
experiments regardless of the absence or presence of effector agents.
Nuclear Run-off Assays--
Nuclear run-off experiments were
carried out as described by us (1, 3) using a LDH-A 3'-UTR cDNA
inserted in Bluescript II KS+ as hybridization probe.
 |
RESULTS |
The Patterns of Decay and Regulation of Chimeric -Globin/ldh
mRNA Stability by Protein Kinases A and C Are Identical to
Wild-type LDH-A mRNA--
Previous studies in our laboratory
demonstrated that intracellular steady-state levels of LDH-A mRNA
are regulated, in part, through modulation of mRNA stability. For
instance, after treatment of rat glioma cells with activators of PKA or
PKC, a dramatic but transient increase of LDH-A mRNA levels takes
place (1, 3). The induced mRNA exhibits a markedly increased
half-life as compared with the relatively short half-life of LDH-A
mRNA in noninduced cells. This indicates that the LDH-A transcript in noninduced cells is targeted for rapid degradation through processes
that can be modulated by effector agents capable of activating the PKA
or PKC signal transduction pathways.
To investigate the molecular basis of the protein kinase-stabilizing
effect, initial studies were carried out to determine whether or not
the decay of wild-type LDH-A mRNA and chimeric globin/ldh mRNA followed similar patterns, justifying
the use of chimeric vectors for subsequent stability studies. By
choosing an expression vector (pRc/FBB) with a serum-inducible
c-fos promoter (15-17), we also avoided artifacts that
potentially occur when commonly used transcriptional inhibitors (18,
19) are used to stop ongoing transcription. We modified pRc/FBB, which
is under the control of a serum-inducible c-fos promoter, by
replacing the BglII/HindIII fragment (Fig.
1), containing the globin 3'-UTR, with
the entire LDH-A 3'-UTR. The resulting chimeric minigene (pRc/FBB/LDH)
was stably transfected into rat C6 glioma cells. After serum
deprivation of cells for 25-30 h, the c-fos promoter was
pulse-induced with fetal calf serum resulting in a brief pulse of
transcription of chimeric -globin/ldh mRNA. Nuclear
run-off assays indicated a rapid induction of nuclear chimeric
globin/ldh transcripts at 15 min (Table
I). After 1 h the level of
transcription had already decreased to levels seen before serum
stimulation. Similar transient kinetics were observed without or with
added DG or (Sp)-cAMPS. Because nuclear
transcription had essentially ceased after 1 h, RNA was
subsequently isolated at various time points, and the rate of decay and
the half-life of chimeric -globin/ldh mRNA were
determined using quantitative ribonuclease protection assays. As
expected from our previous studies (5), wild-type -globin mRNA
was remarkably stable (Fig. 2A, wt
Globin) and decayed with a half-life of about 21 h
(extrapolated from Fig. 2B). In marked contrast, chimeric
-globin/ldh mRNA in unstimulated cells (Fig.
2A, Control) decayed at a much faster rate
(t1/2 65 min) (Fig. 2B) similar to
the half-life of wild-type LDH-A mRNA rate (t1/2 55 min) in glioma cells (1, 3).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 1.
Plasmid pRc/FBB used for the construction of
vectors containing LDH-A 3'-UTR fragments (see text for details).
c-fos SRE represents the serum-inducible
c-fos promoter element.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Nuclear run-off analysis of chimeric globin/ldh mRNA
transcription rates after serum stimulation of transfected rat C6
glioma cells
C6 glioma cells were stably transfected with pRc/FBB/LDH. Serum was
withdrawn for 24-28 h, after which serum and effector agents were
added. At the indicated times after addition, nuclei were isolated and
allowed to incorporate [ -32P]UTP. RNA was isolated,
purified, and hybridized to 2-aminophenylthioether filters carrying
immobilized globin cDNA in Bluescript or wild-type pBluescript (1).
Hybridized radioactivity was eluted from the filters and determined by
liquid scintillation counting. Nonspecific hybridization to wild-type
pBluescript filters was subtracted from the counts/min hybridized to
globin filters. RNA synthesis results are given as the means ± S.E. determined from four separate experiments.
|
|

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 2.
Decay of chimeric globin/ldh
mRNA as a function of time. Rat C6 glioma cells were stably
transfected with plasmid pRc/FBB/LDH in which the entire -globin
3'-UTR had been deleted by restriction with
BglII/HindIII and replaced with the LDH-A 3'-UTR
(nt 1103-1610). After addition of serum and effector agents, RNA was
isolated at various time points up to 12 h. Globin/ldh
mRNA decay was assayed by ribonuclease protection assay, and
half-lives were determined as described under "Experimental
Procedures." A, autoradiographs showing the decay of
globin/ldh mRNA in untreated cells (Control),
and cells treated with DG (200 nM),
(Sp)-cAMPS (0.1 mM), and a
combination of DG and (Sp)-cAMPS. GAPDH was used
as internal control. The decay of wild-type globin mRNA (wt
Globin) is shown for comparison. B, radioactivity was
quantified using a BAS III FUJI radioanalytic imaging scanner. The
results were plotted using nonlinear regression analysis with the
InPlot program. Values are expressed as percentage of zero time. Values
shown in B are the averages of five identical experiments
and are normalized to the control expression level of GAPDH. ,
control; , DG-treated cells; +,
(Sp)-cAMPS-treated cells; ,
DG+(Sp)-cAMPS-treated cells; , wild-type
-globin mRNA.
|
|
Stability of the Chimeric -Globin/ldhmRNA Is
Mediated Synergistically via the Protein Kinase A and C Signal
Pathways--
To examine the effect of protein kinase activation on
the rate of decay of -globin/ldh mRNA, we used the
Sp-isomeric form of adenosine 3', 5' cyclic
monophosphorothioate ((Sp)-cAMPS), a potent
activator of PKA, and DG, a membrane-permeable diacylglycerol analog
that activates PKC (20) and mimicks the effect of endogenous diacylglycerol on PKC (21, 22). As shown in Fig. 2A, DG as well as (Sp)-cAMPS achieved a marked
stabilization of chimeric -globin/ldh mRNA (Fig.
2A, compare Control with DG and
(Sp)-cAMPS). Activation of PKC increased
the half-life of globin/ldh mRNA from about 65 min in
untreated to 4.2 h in TPA- and 3.9 h in DG-treated cells
(Fig. 2B). Activation of PKA with
(Sp)-cAMPS achieved an approximate 7-fold
increase of the half-life of -globin/ldh mRNA from 65 min to 8 h (Fig. 2B).
In view of our previous identification of a synergistic action of PKA
and PKC on LDH-A mRNA stability (3), we examined whether such an
effect also occurred when the chimeric -globin/ldh 3'-UTR
minigene was the transcribed template. Our data show that synergism
was, indeed, demonstrable when a combination of DG + (Sp)-cAMPS was used as activators of the protein
kinase pathways (Fig. 2A, DG + (Sp)-cAMPS). The half-life of
-globin/ldh mRNA increased 18-fold to a half-life of
about 21 h (extrapolated from Fig. 2B). We conclude
from the data that the stability of -globin/ldh mRNA
in glioma cells is similar or identical to wild-type LDH-A mRNA.
Furthermore, the decay patterns of chimeric -globin/ldh mRNA in protein kinase-activated cells appear to follow mechanisms identical to wild-type LDH-A mRNA.
Inhibitors of Protein Kinase C and A Abolish the mRNA
Stabilizing Effect--
To further test the pivotal role of protein
kinase activation in regulation of -globin/ldh mRNA
stability, we used inhibitors that prevent activation of the respective
protein kinase pathway. Exposure of transfected cells to various
activators and inhibitors of PKA and PKC markedly modified the
half-life of -globin/ldh mRNA. As shown in Table
II, the phorbol ester TPA, which binds to
and activates PKC irreversibly (23), caused an approximate 4-fold
increase of -globin/ldh mRNA half-life. Because TPA
may possibly achieve this effect through mechanisms other than
activation of PKC (24), we chose DG as activator. DG is a synthetic
cell membrane-permeable analog of diacylglycerol, the endogenous
activator of PKC, and mimicks the effect of endogenous diacylglycerol
(21, 22). Indeed, DG treatment of transfected glioma cells increased the half-life of -globin/ldh mRNA about 4-fold. The
-isomeric form of phorbol 12 ,13 -didecanoate, which is unable
to activate PKC (25, 26), lacked the stabilizing effect of TPA on
globin/ldh mRNA, strongly suggesting that TPA exerts its
effect through activation of PKC. Furthermore, to prevent activation of
PKC, we used the specific PKC inhibitor bisindolylmaleimide GF 109203X
(BIM) (27). The use of BIM alone did not change the half-life of
globin/ldh mRNA. In combination with DG or TPA, BIM
prevented stabilization of the mRNA. We have already previously
shown that the use of (Rp)-cAMPS, which prevents
activation of PKA, similarly failed to cause stabilization of chimeric
globin/ldh mRNA (3, 5).
View this table:
[in this window]
[in a new window]
|
Table II
Effect of activators and inhibitors of protein kinases A and C on
stability regulation of chimeric globin/ldh mRNA
C6 glioma cells were stably transfected with pRc/FBB in which the
globin 3'-UTR was replaced with the entire LDH 3'-UTR fragment.
Experiments were carried out at about 90% confluence. Serum was
withdrawn for 24-28 h, after which serum and effector agents were
added. One hour after the addition (taken as 0 h time point), RNA
was isolated at various time points up to 12 h. For further
details see "Experimental Procedures." Results are expressed as the
means and S.E. of four separate experiments. PD, phorbol
12 -13 -didecanoate.
|
|
Systematic Analysis of LDH-A 3'-UTR for the Presence of Protein
Kinase C-stabilizing Region(s)--
LDH-A mRNA is characterized by
a moderately short half-life of approximately 55 min (1). Sequence
analysis of its 3'-UTR identifies a 99-nucleotide domain (nt
1450-1549) that is relatively AU-rich when compared with the overall
nucleotide composition of the 3'-UTR. Recently, we have shown that the
3'-UTR imparts a relatively short half-life to LDH-A mRNA because
of the presence of three determinants of instability (5). Although two
of the instability regions are not regulated, one of them, the 22-base 3'-UTR region comprised of nt 1478-1499, is subject to regulation by
the PKA signal pathway. Its presence is an absolute requirement for
cAMP-mediated stabilization of LDH-A mRNA. Using an experimentally similar approach, we now identified putative region(s) within the LDH-A
3'-UTR that are responsible for PKC-mediated stabilization of LDH-A
mRNA. Our strategy consisted of the synthesis of two types of
chimeric globin/ldh 3'-UTR vectors. First, we constructed a
series of globin/ldh 3'-UTR vectors that contained
(a) systematically truncated wild-type 3'-UTR fragments;
(b) mutated 3'-UTR fragments; and (c) 3'-UTRs
from which we had deleted short base regions. The deleted regions were
of approximately similar size to prevent artifactual effects because of
drastic variations in mRNA size. The fragments were inserted into
the unique BglII site of pRc/FBB located at the junction of
the -globin translated and 3'-untranslated regions (Fig. 1) (28). In
the second approach, the entire globin 3'-UTR was deleted by
restriction at the BglII/HindIII sites (Fig. 1)
and replaced with wild-type and various mutated LDH-A 3'-UTR fragments.
Upon stable transfection and transcription of the appropriate vectors,
unique chimeric globin/ldh mRNAs were produced whose stability was assayed by ribonuclease protection assay. Because in each
vector the promoter (c-fos) and globin translation region are identical, the transcripts differ from each other only in their
3'-UTR sequence.
The basal half-lives of truncated wild-type chimeric
globin/ldh mRNAs are shown in Table
III. Whereas several chimeric mRNAs were stable over the time course of the decay period, others exhibited a relatively short half-live without being affected by DG. However, fragment 1471-1502 (and fragment 1463-1502) appears to contain a
PCSR, because treatment of cells with DG resulted in a marked stabilization of the chimeric mRNA (Table III). Interestingly, although a synergistic stabilizing response was observed with chimeric
mRNA in which LDH-A 3'-UTR replaced the entire globin 3'-UTR (Figs.
1 and 2), no synergism was observed with any of the mRNAs
containing a truncated fragment (data not shown).
View this table:
[in this window]
[in a new window]
|
Table III
Effect of dioctanoylglycerol on the half-life of chimeric
globin/ldh mRNAs with inserted LDH-A 3'-UTR fragments
Rat C6 glioma cells were stably transfected with pRc/FBB in which the
listed fragments of LDH-A 3'-UTR (with 5' and 3' BglII ends)
had been inserted into the BglII site of pRc/FBB (see Fig.
1). After stimulation of cells with 200 nM DG, the
half-lives were determined as described under "Experimental
Procedures." Results are expressed as the means and S.E. of four
separate experiments. The half-life of chimeric mRNA transcribed
from pRc/FBB/LDH in which globin 3'-UTR had been replaced with the
complete LDH 3'-UTR (nt 1103-1610) is given for comparison.
|
|
Whereas the above data were obtained by insertion of truncated 3'-UTR
fragments into the BglII site of the globin gene, further analysis was carried out by replacement of the entire globin 3'-UTR with short overlapping fragments generated from the nt 1453-1527 region. This strategy was aimed at preventing any potential artifactual effects on chimeric mRNA stability because of the presence of the
globin 3'-UTR. DG-mediated stabilizing activity was analyzed, and the
half-lives of the resulting chimeric globin/ldh mRNAs are summarized in Table IV.
Comparison of chimeric mRNA derived from insertion of fragment
1463-1527 into pRc/FBB (Table III) with chimeric mRNA in which
fragment 1463-1527 replaced globin 3'-UTR (Table IV) showed not only
similar half-lives but also similar stabilizing effects of DG.
Identical results were obtained when the functional
characteristics (insertion versus replacement) of other
fragments were compared. Based on these data, the fragment consisting
of nt 1463-1502 is the shortest base region so far identified required
for PKC-mediated mRNA stabilization consistent with the data listed
in Table III.
View this table:
[in this window]
[in a new window]
|
Table IV
Effect of dioctanoylglycerol on the half-life of chimeric
globin/ldh mRNAs
The BglII/HindIII fragment containing the entire
globin 3'-UTR in pRc/FBB (see Fig. 1) was deleted and replaced with the
listed fragments of LDH-A 3'-UTR (with 5' BglII and 3'
HindIII ends). Rat C6 glioma cells were stably transfected
with these vectors and stimulated with 200 nM DG, and RNA
decay was assayed as described under "Experimental Procedures."
Results are expressed as the means and S.E. of four separate
experiments.
|
|
Identification of the Location of the Protein Kinase C Stabilizing
Region by Deletion Analysis--
To confirm and expand the above
findings, we analyzed the stability of globin/ldh mRNAs
in which short sequences had been systematically deleted from the
3'-UTR (Fig. 3). The resulting 3'-UTRs were inserted into the
BglII site of pRc/FBB. The vectors were transfected and
transcribed, followed by analysis of the decay characteristics of the
chimeric mRNAs. The results are shown in Table
V. Four 3'-UTRs lacking base regions
located between nt 1286-1462 and 1527-1580 retained DG
responsiveness. On the other hand, when fragments consisting of either
nt 1453-1527, 1463-1482, or 1478-1506 were deleted, two of the
chimeric globin/ldh mRNAs, with deletions at nt
1453-1527 and 1478-1506, exhibited relatively higher basal
half-lives, whereas the globin/ldh mRNA with a deletion
of nt 1463-1482 did not. However, none of the corresponding chimeric
globin/ldh mRNAs were stabilized by DG, indicating that
the deleted fragments contained the complete or at least part of the
PKC-responsive site. These data allow location of the PKC-responsive
site within nucleotides 1453-1506.
View this table:
[in this window]
[in a new window]
|
Table V
Effect of dioctanoylglycerol on the half-life of chimeric
globin/ldh mRNAs containing LDH-A 3'-UTR fragments with
partial deletions
The BglII/HindIII fragment in pRc/FBB (see Fig.
1) was deleted and replaced with LDH-A 3'-UTR from which the listed
fragments had been deleted. Rat C6 glioma cells were stably transfected
with these vectors. After stimulation of cells with 200 nM
DG, the half-lives were determined as described under "Experimental
Procedures."
|
|
A 20-Nucleotide 3'-UTR Region Is Responsible for Stability
Regulation--
To achieve an even more precise delineation of the
active PKC-responsive site, mutational analysis was carried out. We
introduced several mutational changes into fragment 1453-1502, which,
based on above data, contains the region required for PKC-mediated
mRNA stabilization. The resulting chimeric mRNAs were analyzed
for DG responsiveness. The data are shown in Table
VI. Deletion of a -UAA- triplet at nt
1464-1466 (mut1) as well as deletion of two bases at nt 1470-1471
(-UU-) (mut2) did not change the stabilizing effect of DG. Mutation of
bases at 1486-1490 from -CUGUA- to -GACAG- (mut3) maintained the
stabilizing effect although to a somewhat lesser degree. Mutation 4, synthesized from mut3 by deletion of a -UU- doublet at 1484-1485 did
not respond to DG stimulation and lacked the stabilizing effect. A
change of the doublet -UU-at nt 1491-1492 (mut 5) to -GG- did not
affect DG responsiveness. When wild-type fragment 1453-1520 was
inserted into pRc/FBB in the reverse orientation, the instability
effect as well as DG responsiveness were not observed, indicating
that the destabilizing and regulatory effects required a specific
sequence polarity. Thus, mutations introduced upstream of nt 1472 (for
instance at nt 1464-1466 and 1470-1471) (see Table VI) did not
abolish stabilization. Similarly, deletion of sequences downstream of
nt 1492 (see Table IV and V) showed no effect allowing the conclusion
that the region encompassing bases 1472-1491 represents the nucleotide
sequence required for stabilization of LDH-A mRNA via the PKC
pathway.
View this table:
[in this window]
[in a new window]
|
Table VI
Effect of mutational changes within LDH-A 3'-UTR fragment 1453-1520 on
DG-mediated stabilization of chimeric globin/ldh mRNAs
Rat C6 glioma cells were stably transfected with pRc/FBB in which the
listed wild-type (wt) and mutated fragments (mut) had been inserted
into the BglII site of pRc/FBB (see Fig. 1). Cells were
stimulated with 200 nM DG. After isolation of RNA, mRNA
decay was determined as described under "Experimental Procedures."
Results are expressed as the means and S.E. of four separate
experiments. The sequences of the wild-type (wt) and mutated (mut)
fragments are: 1453-1520 wt,
5'-AUCUUGUGCAUAAAUGUUCUACAGGAUAUUUUCUGUAUUAUAUGUGUCUGUAGUGUACAUUGCAAUA-3';
mut1,
5'-AUCUUGUGCA-AUGUUCUACAGGAUAUUUUCUGUAUUAUAUGUGUCUGUAGUGUACAUUGCAAUA-3';
mut2,
5'-AUCUUGUGCAUAAAUG-CUACAGGAUAUUUUCUGUAUUAUAUGUGUCUGUAGUGUACAUUGCAAUA-3';
mut3,
5'-AUCUUGUGCAUAAAUGUUCUACAGGAUAUUUUGACAGUUAUAUGUGUCUGUAGUGUACAUUGCAAUA-3';
mut4,
AUCUUGUGCAUAAAUGUUCUACAGGAUAUU-GACAGUUAUAUGUGUCUGUAGUGUACAUUGCAAUA-3';
mut5,
5'-AUCUUGUGCAUAAAUGUUCUACAGGAUAUUUUCUGUAGGAUAUGUGUCUGUAGUGUACAUUGCAAUA-3'.
A dash indicates base deletion; a bold letter indicates a mutated base.
|
|
 |
DISCUSSION |
Our results strongly support a role for the PKC signal pathway in
the mechanism of LDH-A mRNA stabilization and identify a critical
nucleotide sequence in LDH-A 3'-UTR that is required for PKC-mediated
LDH-A mRNA stabilization. The most critical domain is comprised of
nucleotides 1472-1486, although a somewhat larger region extending to
nucleotide 1491 is required to express the full magnitude of the
stabilizing effect. The region consists of a relatively U-rich (48%)
20-base sequence -CUACAGGAUAUUUUCUGUAU-, which destabilizes -globin
mRNA and responds to PKC activation with a marked mRNA
stabilization. Based on its characteristics, we have named the 20-base
fragment PCSR. Thus, the most significant result described above
consists of the identification of a region (nt 1472-1491) with a dual
function: (a) it is a determinant of LDH-A mRNA
instability and (b) it functions specifically as a modulator
of LDH-A mRNA half-life depending on the state of activation of
PKC.
Perhaps the most surprising finding to come from our work is that CSR
and PCSR contain a 13-nt region (nt 1478-1491; -AUAUUUUCUGUAU-) that
is common to both regulatory elements (Fig.
4). Because
the 13 nucleotides constitute 59% of the CSR and 65% of the PCSR, respectively, the question arises as to the significance of the overlapping arrangement of these two stabilizing regions within the
3'-UTR. One functional property common to both CSR and PCSR, namely
destabilization of LDH-A mRNA, is also exhibited by a class of
short-lived mRNAs that share consensus-like AU-rich motifs in their
3'-UTR (7). Although AU-rich motifs appear to mark mRNA in general
for rapid degradation, it is unlikely that relative nonspecific AU-rich
sequences will participate in the selective regulation of mRNA
stability, such as observed, for instance, for mRNAs that are under
post-transcriptional control by certain effector agents
(e.g. cAMP and DG). Rather, determinants in CSR and PCSR,
other than the 13-nt common sequence, seem to be required to modulate
stability specifically in response to the PKA and PKC signal pathways.
In this fashion the stability and its regulation will be controlled in
a dual mode by relatively nonspecific AU-rich sequences that determine
the relative instability/stability of the mRNA and by sequence
domains that will determine the specificity of the stabilizing
response. Thus, we hypothesize that part of the LDH-A 3'-UTR is
composed of two discrete module(s): (a) the 13-nt
overlapping nonspecific AU-rich determinant in PCSR and CSR and
(b) specific site(s) that in concert with
phospho/dephosphoproteins are instrumental in determining the
specificity of the stabilizing response. These ideas are supported by
our recent identification of four proteins whose specific CSR binding
and mRNA stabilizing effects are achieved through their
phosphorylative modification by PKA (4) in concert with phosphoprotein
phosphatases. Efforts are underway to identify putative PCSR-binding
protein(s) and to analyze their functional properties.

View larger version (8K):
[in this window]
[in a new window]
|
Fig. 3.
Schematic representation of wild-type and
mutant LDH-A 3'-UTRs in pRc/FBB/LDH. The base numbers of deleted
fragments containing the PKC-responsive region are shown in bold
type.
|
|

View larger version (7K):
[in this window]
[in a new window]
|
Fig. 4.
Homologous bases in CSR and PCSR. The
CSR and PCSR are lined up to show the 13-nucleotide homology.
Homologous bases are underlined.
|
|
Our demonstration of a synergism involving PKA/PKC-mediated LDH-A
mRNA stabilization is particularly intriguing (Fig. 2) (3). Importantly, the effect could be duplicated with a chimeric
globin/ldh mRNA, provided the transcribed chimeric
globin/ldh minigene contained the entire wild-type LDH-A
3'-UTR. Truncated 3'-UTR fragments, even though they contain both the
CSR and PCSR, lacked the synergistic effect, and simultaneous
activation of PKA and PKC achieved only an additive increase of
globin/ldh mRNA half-life. Although the PCSR and CSR are
necessary to achieve message stabilization, their presence alone
appears not to be sufficient to obtain a cooperative response, and our
results do not rule out the possibility that secondary structure or
other sequences within LDH-A 3'-UTR may play a role in achieving a
synergism. Nevertheless, synergism suggests a "cross-talk" between
the two signal transduction systems involving
trans-regulatory RNA-binding proteins that are substrates and targets for both PKA and PKC. Cross-talk between two major signal
transduction pathways is a well recognized phenomenon known to occur in
a number of systems (29-31). A mechanism for the two cell surface
receptor coupled signal transduction pathways (PKA and PKC) has been
suggested previously (32). It depends on the presence of serines and
threonines that are specific sites of phosphorylation for
different protein kinases. As mentioned above, our previous studies
have identified several RNA-binding proteins (CSR-BP) that specifically
interact with the CSR and are instrumental in regulating stability (4).
Because CSR and PCSR possess a 13-nt region in common, the distinct
possibility arises that one or more of the CSR-binding proteins are
also substrates for PKC and may be mechanistically involved in the
cooperative effect. However, the understanding of the molecular
mechanism of PKA and PKC-regulated mRNA stability must come from
the cloning of cDNAs encoding the RNA-binding proteins.
A great number of examples of regulated mRNA stability (up- and
down-regulation) in eukaryotic cells by phorbol ester or corresponding second messengers (such as DG) are known (7, 10, 33-44). Although these studies indicate that an increased level of phorbol ester is a
sufficient signal for increased mRNA stability, the molecular mechanisms mediating the effects of phorbol ester have largely remained
obscure. The fact that phorbol ester can activate PKC has led to the
notion that mRNA stability regulation results from a cascade of
events involving PKC isoenzymes and a stabilizing/destabilizing regulatory system such as cis-and trans-acting
factors. Phosphorylative modification of specific RNA binding proteins
would achieve the fine tuning of mRNA half-life. In the case of
LDH-A mRNA, the use of a specific inhibitor of PKC,
bisindolylmaleimide, can abrogate the effect of TPA or diacylglycerol
on mRNA stability, indicating the involvement of PKC in the
stabilization mechanism. These findings are in agreement with previous
reports demonstrating that the stability of ribonucleotide reductase R1
mRNA is increased after phorbol ester treatment of cells. This
phenomenon appears to be mediated through a 49-nt
cis-elements in the 3'-UTR of ribonucleotide preductase
mRNA and its interaction with specific binding proteins (45). A
search for sequence similarities between PCSR and the PKC regulated
ribonucleotide reductase R1 has identified a 3'-UTR region (46)
revealing marked sequence similarities (80% homology) (identical bases
are printed in bold): LDH-A, UUGUGC -AUAAAUG - UUCUACAG - GAUA (nt
1457-1480), and R1,
UUUUGAAAUAAACAUUUCUA - AGUGAUA (nt 2876-2902).
Protein kinase C is a family of at least 10 isoenzymes, all
having closely related structure but differing in their individual functional properties (23, 24). Rat C6 glioma cells express mainly the
, , , and isoforms (47). The , and forms are
activated by phorbol ester and inhibited by bisindolylmaleimide. Thus,
one or more of these three isoforms may mediate the stability regulation of PKC. We are presently investigating the precise nature of
the isoenzyme(s) involved in mRNA stabilization.
Finally, it is appropriate to briefly discuss the physiological
significance and implications of our findings. LDH plays a pivotal role
in normal anaerobic glycolysis. Analysis of the LDH isoenzyme patterns
in different cell types under a variety of physiological conditions
suggests complex regulatory mechanism. The patterns are subject to
regulation by a number of different effector agents, including
17 -estradiol (48, 49), epidermal growth factor (50, 51),
catecholamines (1, 52), phorbol ester (2, 3), hypoxia (53, 54), and
c-Myc (55). These agents almost exclusively change the isoenzyme
pattern in favor of the homotetrameric (A4) isoenzyme
LDH-5. The shifts are attributed to a need for increased A
subunit-containing isoenzymes that are optimally adapted for anaerobic
function. LDH-5 has a low Km for pyruvate and a high
Vmax. It can derive more energy for
the anaerobic cell by reducing pyruvate to lactate with a concomitant generation of NAD+. These situations can occur, for
instance, under conditions of stress-induced activation of
-adrenergic receptors by epinephrine, by hypoxia, phorbol ester- or
c-Myc-induced tumorigenesis, or in tumor cells whose altered metabolic
profiles require a high rate of glucose uptake and increased glycolysis
(56, 57). Complex interrelationships exist between these signals that
regulate LDH-A expression. For instance, evidence has been provided for an interaction of the PKA and PKC pathways (58-61). In systems in
which cAMP is mitogenic, it enhances the expression of c-Myc (62-64)
which, in turn, induces LDH-A expression (55). Furthermore, hypoxic
induction of LDH-A has been functionally linked to PKA activation
involving the CRE and CREB (53, 65). Concomitantly with these events,
activation of PKA leads to a series of amplification cascades that
ultimately lead to increased blood glucose levels and transport (66,
67), conditions that have to be satisfied for increased glycolysis and
lactate production by tumor and hypoxic cells.
 |
ACKNOWLEDGEMENT |
We thank Delai Huang for excellent technical assistance.
 |
FOOTNOTES |
*
This work was supported by Grant GM53115 from the National
Institutes of Health and Neuroscience Training Grant T32NS07140 (to
D. T.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Cell and
Molecular Biology, Northwestern University Medical School, 303 E. Chicago Ave., Chicago, IL 60611. Tel.: 312-908-5275; Fax: 312-503-7107; E-mail: rjungman@nwu.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
LDH or
ldh, lactate dehydrogenase;
UTR, untranslated region;
CSR, cAMP-stabilizing region;
PCSR, protein kinase C-stabilizing region;
nt, nucleotide(s);
(Sp)-cAMPS, adenosine 3', 5'
cyclic monophosphorothioate;
TPA, 12-0-tetradecanoylphorbol-13-acetate;
DG, dioctanoylglycerol;
PKA, protein kinase A;
PKC, protein kinase C;
BIM, 3-[1-(3-dimethylaminopropyl)-indol-3-yl]-3-(indol-3-yl)-maleimide;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
 |
REFERENCES |
| 1.
|
Jungmann, R. A.,
Kelley, D. C.,
Miles, M. F.,
and Milkowski, D. M.
(1983)
J. Biol. Chem.
258,
5312-5318[Abstract/Free Full Text]
|
| 2.
|
Huang, D.,
and Jungmann, R. A.
(1995)
Mol. Cell. Endocrinol.
108,
87-94[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Huang, D.,
Hubbard, C. J.,
and Jungmann, R. A.
(1995)
Mol. Endocrinol.
9,
994-1004[Abstract/Free Full Text]
|
| 4.
|
Tian, D.,
Huang, D.,
Brown, R. C.,
and Jungmann, R. A.
(1998)
J. Biol. Chem.
273,
28454-28460[Abstract/Free Full Text]
|
| 5.
|
Tian, D.,
Huang, D.,
Short, S.,
Short, M. L.,
and Jungmann, R. A.
(1998)
J. Biol. Chem.
273,
24861-24866[Abstract/Free Full Text]
|
| 6.
|
Short, M. L.,
Huang, D.,
Milkowski, D. M.,
Short, S.,
Kunstman, K.,
Soong, C-J.,
Chung, K. C.,
and Jungmann, R. A.
(1994)
Biochem. J.
304,
391-398
|
| 7.
|
Ross, J.
(1995)
Microbiol. Rev.
59,
423-450[Abstract/Free Full Text]
|
| 8.
|
Peng, H.,
and Lever, J. E.
(1995)
J. Biol. Chem.
270,
23996-24003[Abstract/Free Full Text]
|
| 9.
|
Peng, H.,
and Lever, J. E.
(1995)
J. Biol. Chem.
270,
20536-20542[Abstract/Free Full Text]
|
| 10.
|
Ahern, S. M.,
Miyata, T.,
and Sadler, J. E.
(1993)
J. Biol. Chem.
268,
2154-2159[Abstract/Free Full Text]
|
| 11.
|
Levine, R. A.,
McCormack, J. E.,
Buckler, A.,
and Sonesheim, G. E.
(1986)
Mol. Cell. Biol.
6,
4112-4116[Abstract/Free Full Text]
|
| 12.
|
Mitchell, R. L.,
Zokas, L.,
Schreiber, R. D.,
and Verma, I. M.
(1985)
Cell
40,
209-217[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Chen, M.,
Schnermann, J.,
Smart, A. M.,
Brosius, F. C.,
Killen, P. D.,
and Briggs, J. P.
(1993)
J. Biol. Chem.
268,
24138-24144[Abstract/Free Full Text]
|
| 14.
|
Hod, Y.,
and Hanson, R. W.
(1988)
J. Biol. Chem.
263,
7747-7752[Abstract/Free Full Text]
|
| 15.
|
Shyu, A.-B.,
Greenberg, M. E.,
and Belasco, J. G.
(1989)
Genes Dev.
3,
60-72[Abstract/Free Full Text]
|
| 16.
|
Shaw, G.,
and Kamen, R.
(1986)
Cell
46,
659-667[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Greenberg, M. E.,
and Ziff, E. B.
(1984)
Nature
311,
433-438[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Harrold, S.,
Genovese, C.,
Kobrin, B.,
Morrison, S. L.,
and Milcarek, C.
(1991)
Anal. Biochem.
198,
19-29[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Scott, W. A.,
and Tomkins, G. M.
(1975)
Methods Enzymol.
40,
273-293[Medline]
[Order article via Infotrieve]
|
| 20.
|
Berridge, M. J.
(1987)
Annu. Rev. Biochem.
56,
159-193[Medline]
[Order article via Infotrieve]
|
| 21.
|
Boynton, A. L.,
Whitfield, J. F.,
and Kleine, L. P.
(1983)
Biochem. Biophys. Res. Commun.
115,
383-386[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Lapetina, E. G.,
Reep, B.,
Ganon, B. R.,
and Bell, R. M.
(1985)
J. Biol. Chem.
260,
1358-1361[Abstract/Free Full Text]
|
| 23.
|
Nishizuka, Y.
(1984)
Nature
308,
693-698[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Nishizuka, Y.
(1986)
Science
233,
305-312[Abstract/Free Full Text]
|
| 25.
|
Kreibich, G.,
and Hecker, E.
(1970)
Z. Krebsforsch
74,
448-456[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Akiguchi, I.,
Izumi, M.,
and Nagataki, S.
(1993)
J. Endocrinol.
138,
379-389[Abstract/Free Full Text]
|
| 27.
|
Toullec, D.,
Pianetti, P.,
Coste, H.,
Bellevergue, P.,
Grand-Perret, T.,
Ajakane, M.,
Baudet, V.,
Boissin, P.,
Boursier, E.,
Loriolle, F.,
Duhamel, L.,
Charon, D.,
and Kirilovsky, J.
(1991)
J. Biol. Chem.
266,
15771-15781[Abstract/Free Full Text]
|
| 28.
|
van Ooyen, A.,
van den Berg, J.,
Mantei, N.,
and Weissmann, C.
(1979)
Science
206,
337-344[Abstract/Free Full Text]
|
| 29.
|
Houslay, M. D.
(1991)
Eur. J. Biochem.
195,
9-27[Medline]
[Order article via Infotrieve]
|
| 30.
|
Li, Z.,
Vaidya, V. A.,
Alvaro, J. D.,
Iredale, P. A.,
Hsu, R.,
Hoffman, G.,
Fitzgerald, L.,
Curran, P. K.,
Machida, C. A.,
Fishman, P. H.,
and Duman, R. S.
(1998)
Mol. Pharmacol.
54,
14-21[Abstract/Free Full Text]
|
| 31.
|
Morimoto, B. H.,
and Koshland, D. E., Jr.
(1994)
J. Biol. Chem.
269,
4065-4069[Abstract/Free Full Text]
|
| 32.
|
Habener, J.
(1990)
Mol. Endocrinol.
4,
1087-1094[Abstract/Free Full Text]
|
| 33.
|
Sachs, A. B.
(1993)
Cell
74,
413-421[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Shih, S.-C.,
Mullen, A.,
Abrams, K.,
Mukhopadhyay, D.,
and Claffey, K. P.
(1999)
J. Biol. Chem.
274,
15407-15414[Abstract/Free Full Text]
|
| 35.
|
Izzo, N., Jr.,
Tulenko, T. N.,
and Solucci, W. S.
(1994)
J. Biol. Chem.
269,
1705-1710[Abstract/Free Full Text]
|
| 36.
|
Iwai, Y.,
Bickel, M.,
Pluznik, D. H.,
and Cohen, R. B.
(1991)
J. Biol. Chem.
266,
17959-17965[Abstract/Free Full Text]
|
| 37.
|
Lee, N. H.,
Earle-Hughes, J.,
and Fraser, C. M.
(1994)
J. Biol. Chem.
269,
4291-4298[Abstract/Free Full Text]
|
| 38.
|
Ferry, R. C.,
Unsworth, C. D.,
Artymyshyn, R. P.,
and Molinoff, P. B.
(1994)
J. Biol. Chem.
269,
31850-31857[Abstract/Free Full Text]
|
| 39.
|
Shin, K. S.,
Park, J. Y.,
Kwon, H.,
Chung, C. H.,
and Kang, M. S.
(1997)
J. Biol. Chem.
272,
21227-21232[Abstract/Free Full Text]
|
| 40.
|
Bohjanen, P.,
Petryniak, B.,
June, C. H.,
Thompson, C. B.,
and Lindsten, T.
(1991)
Mol. Cell. Biol.
11,
3288-3295[Abstract/Free Full Text]
|
| 41.
|
Akashi, M.,
Loussararian, A. H.,
Adelman, D. C.,
Saito, M.,
and Koeffler, H. P.
(1990)
J. Clin. Invest.
85,
121-129
|
| 42.
|
Kijima, K.,
Matsubara, H.,
Murasawa, S.,
Maruyama, K.,
Ohkubo, N.,
Mori, Y.,
and Inada, M.
(1996)
Hypertension
27,
529-534[Abstract/Free Full Text]
|
| 43.
|
Perrone-Bizzozero, N. I.,
Cansino, V. V.,
and Kohn, D. T.
(1993)
J. Cell Biol.
120,
1263-1270[Abstract/Free Full Text]
|
| 44.
|
Pang, J.-H. S.,
Wu, C.-J.,
and Chau, L.-Y.
(1996)
Biochem. J.
319,
185-189
|
| 45.
|
Amara, F. M.,
Hurta, R. R.,
Huang, A.,
and Wright, J. A.
(1995)
Cancer Res.
55,
4503-4505[Abstract/Free Full Text]
|
| 46.
|
Chen, F. Y.,
Amara, F. M.,
and Wright, J. A.
(1993)
EMBO J.
12,
3977-3986[Medline]
[Order article via Infotrieve]
|
| 47.
|
Chen, C. C.
(1993)
FEBS Lett.
332,
169-173[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Lee, C.,
Oliver, L.,
Coe, E. L.,
and Oyasu, R.
(1979)
J. Natl. Cancer Inst.
62,
193-199
|
| 49.
|
Li, S. S.,
and Hou, E. W.
(1989)
Cell Biol. Intl. Rep.
13,
619-624[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Matrisian, L. M.,
Rautmann, G.,
Magun, B. E.,
and Breathnach, R.
(1985)
Nucleic Acids Res.
13,
711-726[Abstract/Free Full Text]
|
| 51.
|
Boussouar, F.,
and Benahmed, M.
(1999)
Biol. Reproduct.
61,
1139-1145[Abstract/Free Full Text]
|
| 52.
|
Jungmann, R. A.,
Christensen, M. L.,
and Derda, D. R.
(1979)
in
Effects of Drugs in the Cell Nucleus
(Busch, H., ed)
, pp. 507-519, Academic Press, Orlando, FL
|
| 53.
|
Firth, J. D.,
Ebert, B. L.,
and Ratcliff, P. J.
(1995)
J. Biol. Chem.
270,
21021-21027[Abstract/Free Full Text]
|
| 54.
|
Semenza, G. L.,
Jiang, B.-H.,
Leung, S. W.,
Passantino, R.,
Concordet, J.-P.,
Maire, P.,
and Giallongo, A.
(1996)
J. Biol. Chem.
271,
32529-32537[Abstract/Free Full Text]
|
| 55.
|
Shim, H.,
Dolde, C.,
Lewis, B. C.,
Wu, C.-S.,
Dang, G.,
Jungmann, R. A.,
Dalla-Favera, R.,
and Dang, C. V.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
6658-6663[Abstract/Free Full Text]
|
| 56.
|
Dang, C. V.,
and Semenza, G. L.
(1999)
Trends Biochem. Sci.
24,
68-72[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Warburg, O.
(1956)
Science
123,
309-314[Free Full Text]
|
| 58.
|
Field, J. B.,
Ealey, P. A.,
Marshall, N. J.,
and Cockcrofts, S.
(1987)
Biochem. J.
247,
519-524[Medline]
[Order article via Infotrieve]
|
| 59.
|
Cambier, J. C.,
Newell, M. K.,
Justement, L. B.,
McGuire, J. C.,
Leach, K. L.,
and Chen, Z. Z.
(1987)
Nature
18,
629-632
|
| 60.
|
Ziegler, A.,
Knesel, J.,
Fabbro, D.,
and Nagamine, Y.
(1991)
J. Biol. Chem.
266,
21067-21074[Abstract/Free Full Text]
|
| 61.
|
Lombardi, A.,
Veneziani, B. M.,
Toramontano, D.,
and Ingbar, S. H.
(1988)
Endocrinology
123,
1544-1552[Abstract/Free Full Text]
|
| 62.
|
Marcu, K. B.,
Bossone, S. A.,
and Patel, A. J.
(1992)
Annu. Rev. Biochem.
61,
809-860[CrossRef][Medline]
[Order article via Infotrieve]
|
| 63.
|
Pirson, I.,
Coulonval, K.,
Lamy, F.,
and Dumont, J. E.
(1996)
J. Cell. Physiol.
168,
59-70[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Tramontano, D.,
Chin, W. W.,
Moses, A. C.,
and Ingbar, S. H.
(1986)
J. Biol. Chem.
261,
3919-3922[Abstract/Free Full Text]
|
| 65.
|
Ebert, B. L.,
and Bunn, H. F.
(1998)
Mol. Cell. Biol.
18,
4089-4096[Abstract/Free Full Text]
|
| 66.
|
Stein, I.,
Neeman, M.,
Shweiki, D.,
Itin, A.,
and Keshet, E.
(1995)
Mol. Cell. Biol.
15,
5363-5368[Abstract]
|
| 67.
|
Stephens, J. M.,
Carter, B. Z.,
Pekala, P. H.,
and Malter, J. S.
(1992)
J. Biol. Chem
267,
8336-8341[Abstract/Free Full Text]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. Fukui, Y. Ikeda, T. Ohnuki, A. Hikita, S. Tanaka, S. Yamane, R. Suzuki, L. J. Sandell, and T. Ochi
Pro-inflammatory Cytokine Tumor Necrosis Factor-{alpha} Induces Bone Morphogenetic Protein-2 in Chondrocytes via mRNA Stabilization and Transcriptional Up-regulation
J. Biol. Chem.,
September 15, 2006;
281(37):
27229 - 27241.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Pascale, M. Amadio, G. Scapagnini, C. Lanni, M. Racchi, A. Provenzani, S. Govoni, D. L. Alkon, and A. Quattrone
Neuronal ELAV proteins enhance mRNA stability by a PKC{alpha}-dependent pathway
PNAS,
August 23, 2005;
102(34):
12065 - 12070.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. A. Washington, J. M. Reecy, R. W. Thompson, L. L. Lowe, J. M. McClung, and J. A. Carson
Lactate dehydrogenase expression at the onset of altered loading in rat soleus muscle
J Appl Physiol,
October 1, 2004;
97(4):
1424 - 1430.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Kishore, M. R. McMullen, and L. E. Nagy
Stabilization of Tumor Necrosis Factor alpha mRNA by Chronic Ethanol. ROLE OF A + U-RICH ELEMENTS AND p38 MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING PATHWAY
J. Biol. Chem.,
November 2, 2001;
276(45):
41930 - 41937.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Olivi, J. Sisk, and J. Bressler
Involvement of DMT1 in uptake of Cd in MDCK cells: role of protein kinase C
Am J Physiol Cell Physiol,
September 1, 2001;
281(3):
C793 - C800.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Y. Lee, P. Loflin, C. J. Clancey, H. Peng, and J. E. Lever
Cyclic Nucleotide Regulation of Na+/Glucose Cotransporter (SGLT1) mRNA Stability. INTERACTION OF A NUCLEOCYTOPLASMIC PROTEIN WITH A REGULATORY DOMAIN IN THE 3'-UNTRANSLATED REGION CRITICAL FOR STABILIZATION
J. Biol. Chem.,
October 20, 2000;
275(43):
33998 - 34008.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Carpenter, D. Cordery, and T. J. Biden
Protein Kinase Cdelta Activation by Interleukin-1beta Stabilizes Inducible Nitric-oxide Synthase mRNA in Pancreatic beta -Cells
J. Biol. Chem.,
February 9, 2001;
276(7):
5368 - 5374.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|